The UK National Screening Committee is consulting publicly until 4 November on whether an evaluation of screening for screening for severe combined immunodeficiency (SCID) should be undertaken in the NHS.
John is the Evidence Lead for the NHS Screening Programmes. He has worked for the UK National Screening Committee since 2003 and helped establish the evidence team in 2013.
The UK National Screening Committee (UK NSC) makes recommendations on all aspects of population screening. We make recommendations on more than 100 conditions, including recommendations to screen for more than 30.
Non-invasive prenatal testing (now more commonly called cfDNA, or cell-free DNA testing) is an exciting development and the UK NSC is now consulting on introducing it to the existing fetal anomaly screening programme (FASP). As new technology can only be introduced …
Related content and links
The PHE Screening team
Public Health England (PHE) existed to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It closed on 30 September 2021 and this blog is no longer updated.
Find out more about the implications for health screening in our Changes ahead for the national screening system blog article.
If you want to stay in touch with screening evidence and policy news, you can subscribe to the UK National Screening Committee blog.
Comments and moderation
- Changes ahead for the national screening system 30 September 2021
- What we blogged about in August and September 2021 30 September 2021
- New resources to help improve quality of samples taken in NHS newborn blood spot screening 30 September 2021